• We prospectively studied the results of 714 attempts at central venous catheterization during an eight-month period in our intensive care department. We compared the rates of failure of catheterization and early complications among three percutaneous approaches: subclavian, anterior jugular, and posterior jugular veins. The procedures were performed by experienced staff or resident physicians and inexperienced interns and residents under teaching supervision. Overall rates of failure and complication were similar for each percutaneous approach within each group of physicians. Overall failure rate was 10.1% for the experienced group and 19.4% for the inexperienced. The complication was 5.4% for experienced and 11% for inexperienced. Among inexperienced physicians, the success rate was 86.7% and the complication rate 7.6% in unconscious patients, whereas in conscious patients these rates were 70.5% and 13.8%, respectively. The inexperienced physicians caused fewer complications in mechanically ventilated than in spontaneously breathing patients. We suggest that inexperienced physicians should first attempt central vein catheterizations in unconscious and mechanically ventilated patients. (Arch Intern Med1986;146:259-261)

Central Vein Catheterization. Failure and Complication Rates by Three Percutaneous Approaches

Current treatment options for foot ulcers, a serious and prevalent complication of diabetes, remain nonspecific. In this Perspective, we present recent advances in understanding the pathophysiology of diabetic wound healing and the emergence of previously unidentified targets. We discuss wound dressings tailored to the diabetic wound environment currently under development.

Advanced bandages for diabetic wound healing.

Summary.  Background: Few studies have evaluated the long‐term economic consequences of deep vein thrombosis (DVT). None of them have incorporated prospectively collected clinical data to ensure accurate identification of incident cases of DVT and DVT‐related health outcomes of interest, such as post‐thrombotic syndrome (PTS). Objectives: To prospectively quantify medical and non‐medical resource use and costs related to DVT during 2 years following diagnosis, and to identify clinical determinants of costs. Methods: Three hundred and fifty‐five consecutive patients with acute DVT were recruited at seven Canadian hospital centers. Resource use and cost information were retrieved from three sources: weekly patient‐completed cost diaries, nurse‐completed case report forms, and the Quebec provincial administrative healthcare database (RAMQ). Results: The rate of DVT‐related hospitalization was 3.5 per 100 patient‐years (95% confidence interval [CI] 2.2–4.9). Patients reported a mean (standard deviation) of 15.0 (14.5) physician visits and 0.7 (1.2) other healthcare professional visits. The average cost of DVT was $5180 (95% CI $4344–6017) in Canadian dollars, with 51.6% of costs being attributable to non‐medical resource use. Multivariate analysis identified four independent predictors of costs: concomitant pulmonary embolism (relative increase in cost [RIC] 3.16; 95% CI 2.18–4.58), unprovoked DVT (RIC 1.65; 95% CI 1.28–2.13), development of PTS during follow‐up (RIC 1.35; 95% CI 1.05–1.74), and management of DVT in the inpatient setting (RIC 1.79; 95% CI 1.33–2.40). Conclusions: The economic burden of DVT is substantial. The use of measures to prevent the occurrence of PTS and favoring outpatient care of DVT has the potential to diminish costs.

Guanella R, Ducruet T, Johri M, et al. Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: a prospective evaluation

Mesenchymal stromal cells (MSCs) have attracted intense interest due to their powerful intrinsic properties of self-regeneration, immunomodulation and multi-potency, as well as being readily available and easy to isolate and culture. Notwithstanding, MSC based therapy suffers reduced efficacy due to several challenges which include unfavorable microenvironmental factors in vitro and in vivo. In the quest to circumvent these challenges, several modification techniques have been applied to the naive MSC to improve its inherent therapeutic properties. These modification approaches can be broadly divided into two groups to include genetic modification and preconditioning modification (using drugs, growth factors and other molecules). This field has witnessed great progress and continues to gather interest and novelty. We review these innovative approaches in not only maintaining, but also enhancing the inherent biological activities and therapeutics of MSCs with respect to migration, homing to target site, adhesion, survival and reduced premature senescence. We discuss the application of the improved modified MSC in some selected human diseases. Possible ways of yet better enhancing the therapeutic outcome and overcoming challenges of MSC modification in the future are also elaborated. The importance of prosurvival and promigratory abilities of MSCs in their therapeutic applications can never be overemphasized. These abilities are maintained and even further enhanced via MSC modifications against the inhospitable microenvironment during culture and transplantation. This is a turning point in MSC-based therapy with promising preclinical studies and higher future prospect.

/pdf/improved-therapeutics-of-modified-mesenchymal-stem-cells-an-2k7urbozfp.pdf

Improved therapeutics of modified mesenchymal stem cells: an update

Diabetic foot ulcers (DFUs) are very important diabetes-related lesions that can lead to serious physical consequences like amputations of limbs and equally severe social, psychological, and economic outcomes. It is reported that up to 25% of patients with diabetes develop a DFU in their lifetime, and more than half of them become infected. Therefore, it is essential to manage infection and ulcer recovery to prevent negatives outcomes. The available information plays a significant role in keeping both physicians and patients aware of the emerging therapies against DFUs. The purpose of this review is to compile the currently available approaches in the managing and treatment of DFUs, including molecular and regenerative medicine, antimicrobial and energy-based therapies, and the use of plant extracts, antimicrobial peptides, growth factors, ozone, devices, and nano-medicine, to offer an overview of the assessment of this condition.

https://www.mdpi.com/2079-6382/8/4/193/pdf

Diabetic Foot Ulcers: Current Advances in Antimicrobial Therapies and Emerging Treatments

Diabetic foot ulcer (DFU) is a severe complication of diabetes, preceding most diabetes-related amputations. DFUs require over US$9 billion for yearly treatment and are now a global public health issue. DFU occurs in the setting of ischemia, infection, neuropathy, and metabolic disorders that result in poor wound healing and poor treatment options. Recently, stem cell therapy has emerged as a new interventional strategy to treat DFU and appears to be safe and effective in both preclinical and clinical trials. However, variability in the stem cell type and origin, route and protocol for administration, and concomitant use of angioplasty confound easy interpretation and generalization of the results. The PubMed, Google Scholar, and EMBASE databases were searched and 89 preclinical and clinical studies were selected for analysis. There was divergence between preclinical and clinical studies regarding stem cell type, origin, and delivery techniques. There was heterogeneous preclinical and clinical study design and few randomized clinical trials. Granulocyte-colony stimulating factor was employed in some studies but with differing protocols. Concomitant performance of angioplasty with stem cell therapy showed increased efficiency compared to either therapy alone. Stem cell therapy is an effective treatment for diabetic foot ulcers and is currently used as an alternative to amputation for some patients without other options for revascularization. Concordance between preclinical and clinical studies may help design future randomized clinical trials.

/pdf/stem-cell-therapy-for-diabetic-foot-ulcers-a-review-of-3ko222ectu.pdf

Stem cell therapy for diabetic foot ulcers: a review of preclinical and clinical research

Objective Endovenous thermal ablation has become the primary modality of treatment for patients with venous insufficiency. Previous literature has provided reviews of radiofrequency ablation (RFA) or endovenous laser ablation (EVLA) that mostly focus on the great saphenous vein (GSV) and small saphenous vein (SSV). Data with an extended review including the anterior accessory saphenous vein (ASV) and perforator veins (PVs) have been limited. This study examines the treatment of venous insufficiency with RFA and EVLA of these multiple veins to identify clinical and demographic predictors of both the early success and thrombotic complications of endovenous thermal ablation. Methods A retrospective analysis of patients who underwent either RFA or EVLA of the GSV, SSV, ASV, or PVs was performed from March 2012 through February 2014. The PVs were treated only using RFA. The success and complication rates of each method were compared. Procedure results were determined by duplex ultrasound examination at the next office visit. Obliteration of the target vein was defined as a success. A complication was defined as thrombosis of any vein proximal to the target vein or acute thrombosis of any tributaries. Results A total of 808 patients were treated with either RFA or EVLA (2057 procedures); 47 patients were excluded because of incomplete records. In total, 1811 procedures were included with an average of 2.4 procedures per patient. Excluding the PVs, the success rate of RFA was 98.4%, equivalent to EVLA at 98.1% ( P  = .66). The success rates of thermal ablation for each vein were as follows: GSV, 98.5%; SSV, 98.2%; ASV, 97.2%; and PVs, 82.4%. The overall thrombotic complication rate was 10.5%. The thrombotic complications include endovenous heat-induced thrombosis (EHIT; 5.9%) and acute superficial venous thrombosis (4.6%). However, when EHIT class 1 was excluded, the true EHIT rate was 1.16%. The rate of a thrombotic complication for each vein was as follows: GSV, 11.8%; SSV, 5.5%; ASV, 6.5%; and PVs, 2.4%. The thrombotic complication rate was 7.7% for RFA and 11.4% for EVLA ( P  = .007). Age, gender, laterality, presenting symptoms (based on Clinical, Etiology, Anatomy, and Pathophysiology class), and vein type and diameter have no effect on successful ablation. Increased vein diameter ( P P Conclusions There were no statistical difference in successful closure rates between RFA and EVLA. The type of procedure (EVLA), larger vein diameters, and treatment of the GSV were associated with a greater thrombotic complication rate, but type of vein was the most significant independent predictor.

Clinical correlation of success and acute thrombotic complications of lower extremity endovenous thermal ablation.

Recanalization After Endovenous Thermal Ablation

A novel technique for duplex-guided office-based interventions for patients with acute arteriovenous fistula occlusion

Objective Inferior vena cava (IVC) filter retrieval rates remain low. Previous literature identified provider and system factors to enhance retrieval, but patients' perspectives have not been studied. This study compared the attitudes of men and women with retained filters to identify patient factors that would increase compliance and facilitate retrieval when indicated. Methods A retrospective single-center review of all patients undergoing IVC filter placement between 2009 and 2011 was performed. The electronic medical records were reviewed to identify patients with retained filters who were potential candidates for removal. Patients' demographics, comorbidities, and indication for filter placement were noted. A telephone survey inquiring about the patient's awareness of IVC filters and risks of leaving them permanently in place was conducted. Additional questions addressed patient-physician relations, preferences in communication, and attitudes toward television commercials on IVC filter lawsuits. Patients' characteristics and survey responses were compared between men and women. Results There were 604 patients who underwent IVC filter placement. The overall retrieval rate was 30%. Telephone survey was conducted for 42 patients with retained filters who were identified as possible candidates for retrieval. There was no difference between the men and women in terms of demographics and comorbidities. The survey demonstrated that 12% of patients were not aware of having an IVC filter, and only 23% knew that it can be removed. Women were significantly more likely than men to know the risks and benefits of IVC filter placement (42.8% vs 14.2%; P  Conclusions In this era of modern medicine, vascular specialists must educate the patient and family about IVC filters and long-term effects to optimize the patient's compliance. Electronic communication for follow-up may help capture patients who relocate and change phone numbers and seems to be particularly attractive to women.

Afsha Aurshina

Papers

Stem cell therapy for diabetic foot ulcers: a review of preclinical and clinical research

Clinical correlation of success and acute thrombotic complications of lower extremity endovenous thermal ablation.

Recanalization After Endovenous Thermal Ablation

A novel technique for duplex-guided office-based interventions for patients with acute arteriovenous fistula occlusion

Patient perspectives on inferior vena cava filter retrieval.